BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV. It corresponds to a partial sequence of a protein originally descri...
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV. It corresponds to a partial sequence of a protein originally described in human gastric juice and has been studied mostly in animal models of tendon, muscle and gastrointestinal healing.[1][2] Pepitiva supplies BPC-157 as a lyophilized powder (10 mg vials, ≥99% purity, CAS 137525-51-0) for in vitro and preclinical research.[8]
Lyophilized BPC-157
Lyophilization (freeze-drying) removes water from the peptide so it can be stored as a dry powder, which is the standard format for research peptides. Store the powder at −20 °C, protected from light and moisture, and reconstitute it only when needed for an experiment.
Regulatory status
BPC-157 is not approved by the FDA for any use, and its use is banned in professional sports.[7] Recent reviews stress that, despite a large body of animal research, human data are extremely limited: only three small pilot studies have been published.[6]
For research use only. Not for human consumption.
Quality & Storage
≥99% purity. Lyophilized Powder. Storage: -20°C. For research purposes only.
Mechanism of Action
The proposed mechanisms of BPC-157 come from cell and animal studies:
Angiogenesis through VEGFR2: BPC-157 increased vessel density in the chick chorioallantoic membrane and in endothelial tube-formation assays, sped recovery of blood flow in ischemic rat hind limbs, and increased expression and internalization of VEGFR2 (but not VEGF-A) in human endothelial cells, activating the VEGFR2-Akt-eNOS pathway.[4]
Tendon fibroblast migration: it accelerated outgrowth of tendon fibroblasts from explants, improved their survival under oxidative stress and increased their migration in a dose-dependent way, with activation of the FAK-paxillin pathway. It did not directly increase fibroblast proliferation.[2]
Growth hormone receptor: in rat tendon fibroblasts, BPC-157 increased growth hormone receptor expression, and adding growth hormone then increased proliferation through JAK2 signaling.[3]
A 2025 scoping review summarizes these pathways (VEGFR2, Akt-eNOS nitric oxide signaling, ERK1/2) and notes that the effects are reported mainly in poorly vascularized tissues such as tendons and myotendinous junctions.[6] The same systematic review reports that BPC-157 is metabolized in the liver with a half-life of less than 30 minutes and cleared by the kidneys.[7]
Research Applications
Preclinical findings
Achilles tendon transection in rats (2003): daily BPC-157 improved load to failure, functional index and collagen formation, and reduced the size of the tendon defect over 14 days.[1]
Hind limb ischemia in rats (2017): faster blood flow recovery and more vessels in ischemic muscle.[4]
Tendon fibroblasts in vitro (2011, 2014): more migration and spreading, better survival under H₂O₂ stress, and higher growth hormone receptor expression.[2][3]
Human data
Human evidence is very limited. A 2025 pilot study gave intravenous BPC-157 to two adults and reported no changes in heart, liver, kidney, thyroid or glucose markers; the authors call for further studies.[5] A 2025 systematic review identified 35 preclinical studies and a single clinical study, and a 2025 review concludes that BPC-157 should be considered investigational until well-designed clinical trials are conducted.[6][7]
Laboratory research applications
Tendon and ligament models: fibroblast migration, survival and collagen organization.
Angiogenesis assays: VEGFR2 expression and internalization, Akt-eNOS signaling, tube formation.
Gastrointestinal mucosal models: the setting in which the peptide was first described.
Combination tissue-repair studies: often alongside TB-500 (available together as BPC-157 + TB-500) and the copper peptide GHK-Cu. The GLOW blend combines all three, and KLOW adds the anti-inflammatory tripeptide KPV.
This product is sold for laboratory research and is not intended for human or veterinary use.
Storage & Handling Guidelines
Proper storage and handling are essential to maintain peptide integrity and ensure reliable research results. All Pepitiva Biolabs peptides are supplied as lyophilized (freeze-dried) powder, which provides excellent long-term stability when stored correctly. Store lyophilized peptides at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted, peptide solutions should be stored at 2-8°C and used within the timeframe specified in the product documentation. Always use sterile bacteriostatic water for reconstitution and handle peptides in a clean laboratory environment to prevent contamination. Avoid repeated freeze-thaw cycles, as thermal stress can cause peptide degradation and loss of biological activity.
Quality Control & Certification
This product is manufactured under strict quality control protocols and has been verified through comprehensive analytical testing. Each batch undergoes reverse-phase HPLC analysis for purity determination and electrospray ionization mass spectrometry (ESI-MS) for molecular identity confirmation. A detailed Certificate of Analysis (COA) is available for download, documenting purity percentage, molecular weight verification, appearance, and recommended storage conditions. Pepitiva Biolabs maintains batch-level traceability from synthesis through delivery, ensuring complete transparency and quality assurance for your research.
Frequently Asked Questions
What is BPC-157?
A synthetic peptide of 15 amino acids (GEPPPGKPADDAGLV) based on a partial sequence of a protein described in human gastric juice. It is studied in animal models of tissue repair.
What is the molecular weight and CAS number of BPC-157?
Molecular weight 1419.5 g/mol, formula C62H98N16O22, CAS 137525-51-0 (PubChem CID 9941957).
What does lyophilized BPC-157 mean?
Lyophilized means freeze-dried: the peptide is supplied as a dry powder, which is more stable for storage than a solution. It is reconstituted only when needed for an experiment.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any use, and it is banned in professional sports. Human data are limited to a few small pilot studies.
What is the difference between BPC-157 and TB-500?
They are unrelated peptides. BPC-157 is a 15-amino-acid gastric peptide fragment; TB-500 is a synthetic peptide based on thymosin beta-4, an actin-binding protein. See TB-500.
How should BPC-157 be stored?
Keep the lyophilized powder at −20 °C, protected from light and moisture.
Is this product approved for human use?
No. This product is intended exclusively for in vitro scientific research and laboratory use. It is not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and should not be administered to humans or animals under any circumstances.
How do I reconstitute this peptide?
Add sterile bacteriostatic water slowly to the vial, directing the stream against the glass wall rather than directly onto the lyophilized powder. Gently swirl the vial until the powder is fully dissolved — do not shake vigorously. The recommended reconstitution volume depends on your desired concentration. Refer to the product documentation for specific guidance.
Can I get a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis is included with every order and is also available for download from the product page. The COA documents HPLC purity, mass spectrometry identity confirmation, batch number, production date, and storage recommendations.
Scientific References
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PubMed
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. PubMed
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PubMed
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed
Lee E, et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed
McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PubMed
Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed
PubChem. BPC-157, CID 9941957: C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0. Source
Sources are peer-reviewed publications indexed in PubMed and trial registrations on ClinicalTrials.gov. Each citation was checked against its PubMed record.
For research use only. Not for human consumption.
Related Peptides
New≥99%
Metabolic
TB-500
TB-500 is a synthetic research peptide based on thymosin beta-4 (Tβ4), a 43-amino-acid protein that ...
